Aggravated behaviors of hepatocellular carcinoma (HCC) will occur after inadequate thermal ablation. However, its underlying mechanisms are not fully understood. Here, we assessed whether the increased matrix stiffness after thermal ablation could promote the progression of residual HCC. Heat-treated residual HCC cells were cultured on tailorable 3D gel with different matrix stiffness, simulating the changed physical environment after thermal ablation, and then the mechanical alterations of matrix stiffness on cell phenotypes were explored. Increased stiffness was found to significantly promote the proliferation of the heat-treated residual HCC cells when the cells were cultured on stiffer versus soft supports, which was associated with stiffness-dependent regulation of ERK phosphorylation. Heat-exposed HCC cells cultured on stiffer supports showed enhanced motility. More importantly, vitamin K1 reduced stiffness-dependent residual HCC cell proliferation by inhibiting ERK phosphorylation and suppressed the in vivo tumor growth, which was further enhanced by combining with sorafenib. Increased matrix stiffness promotes the progression of heat-treated residual HCC cells, proposing a new mechanism of an altered biomechanical environment after thermal ablation accelerates HCC development. Vitamin K1 plus sorafenib can reverse this protumor effect. R adiofrequency ablation (RFA) has been successfully used for unresectable hepatocellular carcinoma (HCC) at early stage. As reported by Facciorusso et al.
Aggravated behaviors of hepatocellular carcinoma (HCC) will occur after inadequate thermal ablation. However, its underlying mechanisms are not fully understood. Here, we assessed whether the increased matrix stiffness after thermal ablation could promote the progression of residual HCC. Heat-treated residual HCC cells were cultured on tailorable 3D gel with different matrix stiffness, simulating the changed physical environment after thermal ablation, and then the mechanical alterations of matrix stiffness on cell phenotypes were explored. Increased stiffness was found to significantly promote the proliferation of the heat-treated residual HCC cells when the cells were cultured on stiffer versus soft supports, which was associated with stiffness-dependent regulation of ERK phosphorylation. Heat-exposed HCC cells cultured on stiffer supports showed enhanced motility. More importantly, vitamin K1 reduced stiffness-dependent residual HCC cell proliferation by inhibiting ERK phosphorylation and suppressed the in vivo tumor growth, which was further enhanced by combining with sorafenib. Increased matrix stiffness promotes the progression of heat-treated residual HCC cells, proposing a new mechanism of an altered biomechanical environment after thermal ablation accelerates HCC development. Vitamin K1 plus sorafenib can reverse this protumor effect. R adiofrequency ablation (RFA) has been successfully used for unresectable hepatocellular carcinoma (HCC) at early stage. As reported by Facciorusso et al. (1) , RFA achieves complete ablation in more than 90% of very early and early HCC patients. When RFA is being extensively adopted to the treatment of medium-sized or large HCC beyond 3 cm, apparent or occult residual HCC after thermal ablation often occurs at the periphery of the tumor where the target treatment temperature is not reached, leading to cancer cell survival at risk for tumor recurrence. Local tumor recurrence after suboptimal RFA is increased with a reported rate ranging from 10% to as high as 52.4%. (2) (3) (4) Furthermore, the residual or local recurrent tumor showing a more aggressive progression after RFA is being reported more frequently, (5) (6) (7) however, its mechanisms remain unclear.
Multifaceted factors have been reported to be implicated in the acceleration of residual tumor or local recurrence after incomplete RFA. Residual HCC cells after RFA display the sarcomatous transformation, (8) or the elevated expression of invasive and stem cell-like markers. (9, 10) Concurrently, activated inflammatory responses in the microenvironment adjacent to the ablated site may also account for the aggressive progression of residual tumor after RFA, including enhanced expression of angiogenesis-related genes, cytokines, growth factors, and chemokines and the enrichment of inflammatory cells. (11) (12) (13) (14) However, RFA not only destroys the tumor, but also alters the biomechanical environment drastically. Similar to the increased tissue stiffness induced by cardiac RFA, (15) a significant increase in tissue stiffness at the ablated site after liver RFA has been detected by elastography techniques. (16, 17) The potential role of the changed physical attribute of the microenvironment induced by thermal ablation on the malignant behaviors of residual HCC has not been addressed. Given that increase in liver stiffness can favor tumor development, (18) (19) (20) it is reasonable to hypothesize that increased matrix stiffness after RFA, which may constitute the mechanical property of the cancer cell niche, could promote the progression of residual tumor after insufficient RFA.
Here, we show that increased matrix stiffness significantly promotes the proliferation of heat-treated residual HCC cells, which is associated with stiffness-dependent upregulation of the ERK signaling cascade. High matrix stiffness also enhances the motility of heat-exposed residual HCC cells. More importantly, vitamin K1 reduces stiffness-dependent residual HCC cell proliferation and suppressed in vivo tumor growth. This effect is further enhanced by combining with sorafenib treatment. From a new perspective, our work proposes a new mechanism of an altered biomechanical environment after thermal ablation enhances residual HCC development. Vitamin K1 and sorafenib can reverse this protumor effect.
Materials and Methods
Cell culture and sublethal in vitro heat treatment. The human HCC cell lines MHCC97H (established by the Liver Cancer Institute, Zhongshan Hospital of Fudan University, Shanghai, China), Hep3B, and HepG2 (ATCC, Manassas, VA, USA), and Huh7 (obtained from the Japanese Cancer Research Resources Bank, Tokyo, Japan) were cultured in the DMEM supplemented with 10% FBS (Gibco, Carlsbad, CA, USA) and 1% penicillin and streptomycin (Invitrogen, Carlsbad, CA, USA) maintained in a humidified atmosphere with 5% CO 2 at 37°C. When the cells reached near 70% confluence, they were washed, trypsinized, and resuspended in 1 mL DMEM with 10% FBS in 1.5-mL micro-centrifuge tubes (5 9 10 4 cells). They were then were subjected to heat treatment with predetermined temperatures (37°C, 43°C, 45°C, 46°C, 47°C, 48°C, 50°C, and 55°C) for 10 min in an isothermic water bath incubator (Jing Hong Laboratory Instrument Co., Ltd., Shanghai, China). Thereafter, heat-treated cells were seeded into 96-well culture plates in quadruplicate for every temperature and cultured at 37°C for 48 h. Culture media were replaced three times per day to remove dead cells and debris. Absorbance was measured using WST-1 (Roche Diagnostics, Mannheim, Germany) on a Multiskan Spectrum reader (Thermo Fisher Scientific, Waltham, MA, USA) to determine cell viability. The temperature causing 50-% reduction in cell viability relative to the 37°C control (IT 50 ) was calculated using non-linear regression curve-fitting by Prism 6.0 (GraphPad Software, San Diego, CA, USA). The IT 50 data were used for subsequent experiments to simulate the in vitro sublethal heat treatment condition.
Cell proliferation. The 24-well plates were precoated with Cell Culture Gel with three different stiffness (soft, medium, and stiff) with strength ranging from 1 kPa to 40 kPa (101 Bio, California, USA) according to the manual's instructions. Heat-treated residual HCC cells were seeded into the precoated plates and cultured at 37°C for 48 h. Cell proliferation was determined using the WST-1 cell proliferation assay (Roche Diagnostics). The absorbance was measured at a wavelength of 440 nm with a reference wavelength of 650 nm using a microplate reader.
For individual experiments, heat-treated residual HCC cells seeded into the precoated medium stiffness plates were exposed to 25 lM U0126 (Cell Signaling Technology, Beverly, MA, USA), 5 lM sorafenib (Santa Cruz Biotechnology, Santa Cruz, CA, USA), 200 lM vitamin K1 (Sigma, St. Louis, MO, USA), 200 lM vitamin K1 plus 25 lM U0126, or 200 lM vitamin K1 plus 5 lM sorafenib for 36 h, then the cell proliferation was determined using the WST-1 assay as described above.
Quantitative RT-PCR. Total RNA of samples was extracted using TRIzol reagent (Ambion, Carlsbad, CA, USA), of which 2 lg was synthesized into cDNA using RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). Gene expression was measured with Maxima SYBR Green qPCR Master Mix (Thermo Fisher Scientific), and analyzed by the Ct method, normalized to that of human GAPDH and calculated by the 2 ÀDDCt method. The primer sequences are listed in Table S1 . Western blot analysis. Total proteins were extracted with an ice-cold RIPA lysis buffer containing 1 mM PMSF (Beyotime Institute of Biotechnology, Shanghai, China) and 10% Phos-STOP phosphatase inhibitor Cocktail (Roche). Equivalent amounts of proteins (20 lg) quantified by a bicinchoninic acid protein kit (Millipore, Massachusetts, USA) were separated using 10% SDS-polyacrylamide gels and then transferred to PVDF membranes (Millipore, USA). Membranes were incubated overnight at 4°C with primary antibodies against proliferating cell nuclear antigen (PCNA) (1:2000; Cell Signaling Technology), ERK1/2 (1:1000; Cell Signaling Technology), Phosopho-ERK1/2 (Thr202/Tyr204) (1:2000; Cell Signaling Technology), GAPDH (1:1000; Beyotime Institute of Biotechnology) and appropriate HRP-conjugated secondary antibodies (Jackson Laboratories, West-Grove, PA, USA) for 1 h at room temperature. Thereafter, the chemiluminescent signals were visualized by Ncm-ECL Ultra (New Cell & Molecular Biotech Co., Ltd, Suzhou, China).
Extracellular signal-regulated kinase 1/2 blocking assay. Heattreated residual HCC cells plated at medium stiffness were incubated with ERK1/2 inhibitor and/or vitamin K1 for 6 h or 48 h. Then the proteins were extracted for Western blot analysis.
Immunocytochemistry. Heat-treated residual HCC cells were grown on 6-well plates precoated with Cell Culture Gel of different stiffness, fixed in 4% paraformaldehyde, and permeabilized with 0.1% Triton X-100 in PBS for 10 min. Fixed cells were stained with phalloidin-TRITC (50 lg/mL; Sigma) for 40 min, protected from light. Nuclei were counterstained with DAPI (Beyotime Institute of Biotechnology) for 5 min. Cells images were captured with a fluorescence microscope under appropriate excitation and emission filters (Leica, Wetzlar, Germany).
Immunohistochemistry. Briefly, paraffin-embedded tissue sections were deparaffinized in xylene, rehydrated through graded ethanol, and underwent antigenic retrieval and endogenous peroxidase blocking. Subsequently, sections were blocked with 2% BSA and incubated with primary antibodies PCNA (1:400; Cell Signaling Technology) and phospho-ERK1/2 (Thr202/Tyr204, 1:200; Cell Signaling Technology) at 4°C overnight followed by the EnVision two-step visualization system (GeneTech Company Limited, Shanghai, China). The slides were counterstained with hematoxylin and mounted. The staining was determined by three randomly selected fields under the microscope.
Live-cell microscopy. Tumor multicellular spheroids were transferred to 6-well culture plates coated with different stiffness. Following attachment, cells were imaged using a Cell-IQ cell culturing platform (Chip-Man Technologies, Tampere, Finland) equipped with a phase-contrast microscope (Nikon CFI Achromat phase contrast objective with 9200 magnification) and a camera (Nikon, Fukasawa, Japan). Images were captured at 5-min intervals for 24 h. The images were analyzed using NIH ImageJ software (National Institutes of Health, Bethesda, MD, USA) with the MTrackJ Plugin to depict the cumulative track travelled by the cells with the use of the center of each cell nucleus as the point of tracking.
Animal experiments. Animal experimental protocols were carried out in compliance with the relevant guidelines formulated by the Shanghai Medical Experimental Animal Care Commission and approved by the Animal Ethics Committee of Shanghai Medical College of Fudan University. All mice were purchased from SLAC Laboratory Animal Co., Ltd., Shanghai, China.
Male BALB/c nude mice weighing 18-20 g at 4-6 weeks of age were injected s.c. with 5 9 10 6 heat-treated residual HCC cells suspended in Cell Culture Gel of soft or medium stiffness mixed with Matrigel at a ratio of 4:1 (n = 3, each group) into the upper right flank of each mouse. The estimated tumor weight was evaluated with Vernier caliper every 4 days by the calculation formula: length (mm) 9 (width (mm)) 2 /2. Another 20 mice bearing tumors generated from heat-treated residual HCC cells with medium stiffness gel were randomly divided into four groups: i.p. injected with DMSO (control; n = 5), vitamin K1 (2 mg/kg, daily; n = 5), sorafenib (1.25 mg/kg, daily; n = 5) or vitamin K1 combined with sorafenib treatment (vitamin K1, 2 mg/kg; sorafenib 1.25 mg/kg; daily; n = 5). The treatments were continued for 2 weeks. Animals were killed 48 h after the last treatment, and tumors were excised, weighed, and placed in liquid nitrogen and formalin for further analysis.
Statistical analysis. Data are presented as means AE standard deviation. Differences between two or multiple groups were processed using Student's t-test or one-way ANOVA with SPSS 17.0 software (SPSS, Chicago, IL, USA) or GraphPad Prism software (GraphPad Software). P-values below 0.05 were considered statistically significant.
Results
Increased matrix stiffness promoted the proliferation and progenitor-like traits of heat-exposed residual HCC cells. Based on IT 50 data calculated from heat stress dose-response curves of Hep3B (47.04°C) and HepG2 cells (46.88°C) (Fig. 1a) , and MHCC 97H (46.26°C) and Huh7 cells (47.37°C) (data not shown), 47°C for 10 min was selected as the condition of sublethal heat treatment to simulate incomplete thermal ablation in vivo.
Morphologies of heat-exposed residual HCC cells on the different stiffness gels shifted from small and round towards proliferative, outstretched, and spindle-like in appearance as the culture stiffness increased after 48 h of culture (Fig. 1b) . The heat-exposed residual cells cultured on medium or stiff supports had a higher proliferative activity than those cells on the soft gels (Fig. 1c) . This was paralleled by the significant increase of proliferation-related transcripts (PCNA and CyclinD1) (Fig. 1d) . Consistent with this finding, cells proliferated faster as stiffness was elevated, paralleled by a significant increase of PCNA at the protein level (Fig. 1e) . The medium , and CK19 mRNA expressions in heat-treated residual MHCC97H and HepG2 cells on medium stiffness gels compared with cells cultured on soft gels. *P < 0.05; **P < 0.01. stiffness gel was selected for subsequent experiments because its yielded strength ranged from 14 to 20 kPa, which simulates increased liver stiffness after thermal ablation. (16, 17) Compared with the heat-exposed residual cells cultured on the soft gels, transcripts of the putative stem cell markers EpCAM and cholangiocyte markers CK7 and CK19 were dramatically elevated in the cells on the medium stiffness gels (Fig. 1f) . These results show that the increased stiffness endows the heat-treated residual HCC cells a highly proliferative and progenitorlike cellular phenotype in vitro.
Increased matrix stiffness enhanced the motility of heatexposed residual HCC cells. We next sought to assess the motility of the residual HCC cells coordinated by matrix stiffness. Cell migration has been tightly linked to cancer progression and metastasis. (21) An in vitro model mimicking the metastatic processes has been developed by the reversal of multicellular spheroids to a monolayer. (22) Multicellular spheroids from heattreated residual HCC cells were generated under anchorageindependent growth, then transferred into different stiffness gels. The distance of cell migration from their bases was compared (Fig. 2) . When the multicellular spheroids were cultured on the medium stiffness gels, the cells showed vigorous motility and were detached and disseminated extensively into gels. In contrast, the cells cultured on the soft gels showed indolent behavior and compact growth. These results indicate that higher stiffness promotes the motility of heat-exposed residual HCC cells to show stronger invasive and metastatic propensities.
Matrix stiffness modulated the cellular phenotypes of heatexposed residual HCC cells. To establish bidirectional validation whether matrix stiffness would alter the malignant behaviors of heat-exposed residual HCC cells, we first cultured residual HCC cells on soft or medium stiffness gels and then transferred them to another stiffness environment (Fig. 3a) . We tested the reciprocal combinations including transfer from soft to medium stiffness gel, from medium stiffness to soft gel, from soft to soft gel, and from medium to medium stiffness gel (Fig. 3b) . The cell motility of the residual HCC cells was assessed by phalloidin staining of F-actin. Transfer from soft to medium stiffness gel resulted in higher proliferative growth and spreading migration in the new environment, whereas transfer from medium stiffness to soft gel resulted in a retraction of protrusions and rounded growth. Transfer between soft and soft gel, or between medium and medium stiffness gel resulted in cells sustaining their original morphological features. In parallel with the morphologic changes, the levels of PCNA and CyclinD1 mRNA expression fluctuated when the culture environment was shifted from medium to soft stiffness. These data show that the matrix stiffness microenvironment can modulate the proliferative and motile phenotypes of heatexposed residual HCC cells.
Activation of ERK was induced by stiffness in heat-exposed residual HCC cells. We analyzed the stiffness-associated activation of ERK in the heat-exposed residual HCC cells. Compared with the residual cells cultured on soft gels, obvious elevation of the phosphorylated ERK was observed in cells on the medium stiffness gels. However, ERK inhibitor (U0126) or vitamin K1 was able to inhibit stiffness-induced ERK phosphorylation in the residual cells, as well as decrease the expression of the proliferation-related protein (PCNA). Combined treatment with vitamin K1 plus U0126, substantially decreased ERK activation and PCNA expression (Fig. 4a) . Moreover, proliferation and morphology change of heat-treated residual HCC cells (MHCC97H and Huh7) on the medium stiffness gels were significantly inhibited by U0126, sorafenib, vitamin K1, vitamin K1 plus U0126, and vitamin K1 plus sorafenib (Fig. 4b,c) . These data indicate that higher matrix stiffness promotes ERK activation and proliferation in heatexposed residual HCC cells, which can be blunted by sorafenib, ERK inhibitor, and/or vitamin K1.
Stiffness promoted in vivo progression of heat-treated residual HCC cells. To probe the effects of stiffness on the growth dynamics of heat-exposed residual HCC cells in vivo, residual HCC cells (MHCC97H) embedded in the soft or medium stiffness gel were s.c. inoculated into nude mice. Our results showed that the growth of tumors from residual HCC cells mixed with medium stiffness gels was significantly promoted, compared with that of tumors formed from residual cells with soft gels (Fig. 5a ). Real-time PCR and immunohistochemistry indicated that the levels of PCNA, CyclinD1, EpCAM, CK7, and CK19 mRNA expression and the protein levels of PCNA and ERK phosphorylation were increased in tumors generated from residual HCC cells mixed with medium stiffness gels (Fig. 5b,c) . These data suggest that stiffness can promote the in vivo progression of residual HCC cells through ERK activation and enhanced proliferation.
Vitamin K1 plus sorafenib suppressed the stiffness-enhanced progression of heat-exposed residual HCC in vivo. To validate whether vitamin K1 and/or sorafenib could block the stiffnessenhanced progression of heat-exposed residual HCC, residual HCC cells embedded in the medium stiffness gel were transplanted s.c. into nude mice. The mice were treated with either vitamin K1 or sorafenib or the combination of both agents. Our results showed that vitamin K1 or sorafenib alone inhibited tumor growth slightly, whereas the combination of vitamin K1 with sorafenib caused major tumor shrinkage (Fig. 6a) . In parallel with the reduction in tumor growth, the levels of PCNA, CyclinD1, EpCAM, CK7, and CK19 mRNA expression and the decreased staining of PCNA and ERK phosphorylation were found in tumors treated with vitamin K1 plus sorafenib (Fig. 6b,c) . These findings indicate that vitamin K1 plus sorafenib can abrogate the stiffness-initiated progression of heatexposed residual HCC cells in vivo.
Discussion
Radiofrequency ablation has gained popularity in the management of unresectable small HCC due to its superiority in terms of effectiveness, minimal invasiveness, safety, and repeatability. (23) However, when RFA is used for HCCs 3 cm or larger, its treatment efficacy decreases due to the high rate of local tumor recurrence. (3) Local tumor recurrence appears to arise from undertreated minimal or occult residual disease, microsatellites after suboptimal RFA, or because of failure to ensure a sufficient safety margin when ablating a larger tumor. (24) Moreover, local recurrent tumor after incomplete RFA shows a more invasive progression, (5) (6) (7) (25) (26) (27) although its mechanism remains unclear. Here, we reveal that increased matrix stiffness, which will occur after RFA treatment, promotes the proliferation, motility, and progression of heatexposed residual HCC cells. More importantly, vitamin K1 and sorafenib can reverse this protumor effect. These findings will help design strategies to treat the local recurrence and prevent its rapid progression after RFA in the treatment of medium-sized and large HCC.
Most HCCs occur in the setting of cirrhosis. Increased stiffness of liver cirrhosis is caused by excessive ECM deposition. It has been reported that increasing matrix stiffness promotes the proliferation and chemotherapeutic resistance of HCC. (18) In our previous work, we showed that higher matrix stiffness increases vascular endothelial growth factor and Fig. 6 . Vitamin K1 plus sorafenib inhibits the stiffness-induced progression of heat-exposed residual hepatocellular carcinoma in vivo. (a) Vitamin K1 and sorafenib separately suppressed tumor growth, and the suppression was markedly enhanced by the combination of both agents. (b) PCNA, CyclinD1, EpCAM, CK7, and CK19 mRNA expressions in tumors generated from heat-treated residual MHCC97H cells with medium stiffness gels were measured using quantitative RT-PCR. (c) Immunohistochemical analysis was carried out to compare the expression of proliferating cell nuclear antigen (PCNA) and p-ERK in tumors from the four groups. *P < 0.05; **P < 0.01. Fig. 7 . Proposed graphical diagram of increased matrix stiffness promoting tumor progression of heat-exposed residual hepatocellular carcinoma (HCC) cells. Increased matrix stiffness after heat treatment activates ERK phosphorylation to modulate the progression of heat-exposed residual HCC cells. Vitamin K1 plus sorafenib can reverse this protumor effect.
osteopontin secretion and stem-like characteristics to promote HCC progression. (20, 28, 29) Radiofrequency ablation ablates the tumor and leads to dramatic changes in the mechanical properties of the tumor environment, that is, it further increases the local tissue stiffness. (16, 17) In this study, we showed that increased matrix stiffness promotes the progression of heat-treated residual HCC cells, which will help to explain accelerated disease progression after incomplete RFA. Different from the previous reports that focused on the response of HCC cells themselves to sublethal heat, (9, 10, (30) (31) (32) (33) (34) we propose a new mechanism of post-RFA increased stiffnessdependent residual tumor progression, namely, heat-treated residual HCC cells can sense the increased matrix stiffness after RFA to accelerate the tumor progression.
In this study, we found that activation of the ERK pathway contributes to the stiffness-induced proliferation, motility, and progression of heat-treated residual HCC cells. Phosphorylation of ERK can mediate mechanotransduction. (18) Furthermore, it is also involved in the regulation of cell proliferation and malignant tumor progression including HCC. (10, 18, 33, 35) Vitamin K has antitumor activity on oral, pancreatic, and hepatic cancers as a single agent or combined with other therapeutic agents including sorafenib. (36) (37) (38) Sorafenib has been approved as the molecular target drug for advanced HCC by suppressing the RAS/RAF/MEK/ERK signal transduction pathway. (39, 40) In this study, vitamin K1 plus sorafenib is shown to synergistically and markedly inhibit matrix stiffness-induced ERK activation and in vivo tumor progression. This result is consistent with previous reports that vitamin K1 with sorafenib exerts an additive inhibitory effect on ERK signaling. (39) The combination of sorafenib with RFA significantly decreased post-RFA HCC recurrence in the treatment of small and medium-sized HCC. (41) (42) (43) Our findings suggest that the potential treatment strategy of RFA combined with vitamin K1 plus sorafenib could further decrease local tumor recurrence after RFA treatment for medium and large HCC (Fig. 7) .
In conclusion, our study shows that increased matrix stiffness promotes the progression of heat-treated residual HCC cells and proposes a new mechanism of the altered biomechanical environment after RFA accelerating residual HCC development. Vitamin K1 and sorafenib disrupt the stiffnessinduced ERK activation to reverse this protumor effect, as potential therapeutic drugs.
